Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.97 USD
Change Today -0.12 / -1.19%
Volume 582.1K
VNDA On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

vanda pharmaceuticals inc (VNDA) Snapshot

Open
$10.02
Previous Close
$10.09
Day High
$10.07
Day Low
$9.64
52 Week High
06/30/14 - $16.50
52 Week Low
10/13/14 - $8.34
Market Cap
415.2M
Average Volume 10 Days
445.5K
EPS TTM
$-0.98
Shares Outstanding
41.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VANDA PHARMACEUTICALS INC (VNDA)

vanda pharmaceuticals inc (VNDA) Related Businessweek News

No Related Businessweek News Found

vanda pharmaceuticals inc (VNDA) Details

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company’s products include HETLIOZ, a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a product for the treatment of schizophrenia. Its products also include Tradipitant, a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis; Trichostatin A, a small molecule histone deacetylase inhibitor; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

64 Employees
Last Reported Date: 03/13/15
Founded in 2002

vanda pharmaceuticals inc (VNDA) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $515.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $315.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $279.8K
Compensation as of Fiscal Year 2013.

vanda pharmaceuticals inc (VNDA) Key Developments

Vanda Pharmaceuticals, Inc. Announces Tom Gibbs as Senior Vice President, Chief Commercial Officer

Vanda Pharmaceuticals Inc. announced that it has named Tom Gibbs as Senior Vice President, Chief Commercial Officer of the company. Prior to joining Vanda, Mr. Gibbs served as Vice President of Worldwide Commercial Operations at Bristol Myers Squibb. Prior to this position, Mr. Gibbs held other senior roles at Bristol Myers Squibb including Vice President of US HIV Franchise and Vice President Global Commercialization and FDT Leader HCV Portfolio and HCV Small Molecules. Before joining Bristol Myers Squibb, Mr. Gibbs held the position of Vice President of US Sales for Novartis Vaccines and Diagnostics. Earlier in his career, Mr. Gibbs held positions at Endo Pharmaceuticals, Johnson & Johnson Corporation, George Weiss Associates and SmithKline Beecham PLC.

Vanda Pharmaceuticals Inc. Announces Nominating/Corporate Governance Committee Changes

Vanda Pharmaceuticals Inc. announced that on March 16, 2015, Steven K. Galson, M.D., M.P.H. notified the Board of Directors of the company that he did not intend to stand for re-election at the company's 2015 Annual Meeting of Stockholders so that he may devote his full time efforts to his other commitments. The Board has appointed Richard Dugan, a current director, to succeed Dr. Galson as a member of the Nominating/Corporate Governance Committee of the Board, effective upon the expiration of Dr. Galson's term.

Vanda Pharmaceuticals Inc. Announces Top-Line Results of the Phase II Proof of Concept Clinical Study

Vanda Pharmaceuticals Inc. announced top-line results of the Phase II proof of concept clinical study investigating the safety and efficacy of tradipitant as a monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis. Tradipitant, formerly known as VLY-686, is a neurokinin 1 receptor antagonist under clinical investigation for the treatment of chronic pruritus in patients with atopic dermatitis. The pre-specified primary endpoint of the Phase II proof of concept clinical study was the change from baseline on the Visual Analog Scale (VAS) for itch. Due to high placebo effect, there was no significant difference from placebo on this pre-specified endpoint, however, Vanda believes this proof of concept study was informative, in that through subsequent analyses, it has discovered an exposure response relationship and further observed a significant and clinically meaningful response across several pruritus related outcomes evaluated in individuals with higher blood plasma levels of tradipitant. This is not unexpected given that all the assessments related to pruritus are significantly associated with the itch sensation the patient is experiencing at that time. Based on the data Vanda examined across the study, lower blood plasma levels of tradipitant may be below a threshold of efficacy to ameliorate the itch sensation in patients.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $9.97 USD -0.12

VNDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,750 GBp -80.50
Bristol-Myers Squibb Co $65.80 USD -0.20
Eli Lilly & Co $71.58 USD -0.82
Pernix Therapeutics Holdings Inc $7.09 USD -0.24
Sanofi €95.86 EUR +0.51
View Industry Companies
 

Industry Analysis

VNDA

Industry Average

Valuation VNDA Industry Range
Price/Earnings 18.3x
Price/Sales 7.6x
Price/Book 2.6x
Price/Cash Flow 18.7x
TEV/Sales 5.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit www.vandapharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.